MIBG W/ INTENSIVE CHEMOTHERYAPY & AUTOLOGOUS STEM CELL RESCUE FOR NEUROBLASTEMA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 神经母细胞瘤是儿童最常见的实体瘤之一。尽管化疗和放疗取得了现代进展，但目前治愈大多数神经母细胞瘤患者的能力<40%。对初始化疗（称为诱导治疗）无效的患者或肿瘤复发的患者治愈的机会更低。此类患者的治愈率<10%。 该方案的目的是治疗那些最有可能死于癌症的患者-复发性神经母细胞瘤患者或诱导治疗失败的患者。患者将接受一种名为131-I MIBG的放射性化学物质治疗。 希望是MIBG将专门向肿瘤提供辐射，从而使身体其他部位免受辐射的影响。'

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Neuroblastomas are one of the most common solid tumors of childhood. Despite modern advances in chemotherapy and radiation therapy, the ability to cure most patients with neuroblastoma is currently < 40%. Patients who fail to respond to initial chemotherapy (called induction therapy), or those patients whose tumors relapse have even a much lower chance for cure. The cure rate for such patients is < 10%. The purpose of this protocol is to treat those patients with the greatest chance of dying from their cancer - those patients with relapsed neuroblastoma or those who fail induction therapy. The patients will be treated with a radio-active chemical called 131-I MIBG. The hope is that the MIBG will deliver radiation specifically to the tumor, thereby sparing the rest of the body the effects of the radiation.'